CHLOROQUINE AND HYDROXYCHLOROQUINE LIPOSOMES FOR INHALATION
Aims to inhibit intracellular processing of the virus that has reached cells in the lung, using a different formulation and active ingredient with completely different modes of action than Project 1. A well-established and clinically used active pharmaceutical ingredient targeting infected lungs is being repurposed and a trial formulation is ready for lab models
1 out of 3 technologies of Chezy of liposomal drugs for the treatment of COVID-19
in website all3 under 10906
Project ID : 47-2020-10906
Prof. Barenholz is focusing his lab activities on three projects, all aimed at re-purposing drugs with known active ingredients for treatments of viral infection.
Project 1: Aims to stop and/or reduce viral penetration and the severe inflammation caused by the viral infection by repurposing a well-established and clinically used active pharmaceutical ingredient targeting infected lungs. A trial formulation is ready for lab models.
Project 2: Aims to inhibit intracellular processing of the virus that has reached cells in the lung, using a different formulation and active ingredient with completely different modes of action than Project 1. A well-established and clinically used active pharmaceutical ingredient targeting infected lungs is being repurposed and a trial formulation is ready for lab models.
Project 3: Aims to treat Acute Respiratory Distress Syndrome (ARDS), the last stage of a viral infection that can lead to severe morbidity and death. This is a collaboration with Prof. Yoram Weis of Hadassah-University Hospital and the University of Lausanne (Switzerland) who have shown the feasibility of this approach in treatment of ARDS. This is currently in the formulation stage, and ready with all the reagents and assay required for development. This Project is a completely different approach from Projects 1 and 2 and is based on a totally different active ingredient.
Projects 1-3 have promising potential based on in vitro or lab model studies
Project manager
Keren-Or Amar
VP, Business Development, Healthcare
Project researchers
Yechezkel Barenholz
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology
Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from Israel
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.
Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Yissum - Research Development Company of the Hebrew University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
